% | $
Quotes you view appear here for quick access.

Peregrine Pharmaceuticals, Inc. Message Board

  • laujhawj laujhawj Feb 13, 2013 8:41 AM Flag

    Remember what CELG's Scientists Said About Abraxane last month

    And that was: Pancreatic cancer is so tough to deal with, getting the "needle to move at all" is a big achievement, whenever you could actually get it to move at all!


    PPHM's folks are saying the same thing; so the imrovement IS REAL, albeit "modest", as Menander said.

    "We are pleased with the results seen in this very difficult to treat patient population," said Kerstin Menander, MD, PhD, head of medical oncology at Peregrine. "Although the median overall survival improvement is modest, further analysis of the data including subgroups shows some very interesting and potentially promising trends. We look forward to presenting the full data set from this trial later this year at an upcoming scientific meeting."


    Let's hope we hear and read about the MORE DETAILED analysis of the double-blind second line NSCLC later this week, too, so PPHM could really get back up to the $500-$700M market cap range...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.39-0.04(-2.80%)Apr 17 4:00 PMEDT